Overview
Elizabeth Harrington received her master’s degree in Human Genetics and Genetic Counseling from the Stanford School of Medicine and her BA in Biology with a minor in Communicative Disorders from the University of Redlands. Ms. Harrington is a neurogenetics clinical and research genetic counselor with expertise in Motor Neuron Disease (MND). She provides genetic counseling and testing for those neuromuscular diseases, primarily with Amyotrophic Lateral Sclerosis (ALS).
Ms. Harrington directs the ALS Families Project research study, a presymptomatic natural history study designed to understand the genetic underpinnings of genetic forms of ALS and the impact on affected families. In addition to overseeing the longitudinal component of the study, she provides predictive genetic counseling services to asymptomatic individuals who are at risk of having inherited an ALS-associated genetic variant. Ms. Harrington is the Pre-Clinical Silence ALS Program genetic counselor and coordinator, a study aimed to discover and develop personalized experimental antisense oligonucleotide (ASO) medicines for ALS patients with rare, disease-causing gene mutations.
Ms. Harrington joined the Department of Neurology faculty in 2019 and is a Lecturer in Genetic Counseling. She is the course director for Biochemical Genetics and Neurogenetics Fieldwork Supervisor for the master’s degree program in Genetic Counseling at the Columbia University Vagelos College of Physicians and Surgeons.
Ms. Harrington directs the ALS Families Project research study, a presymptomatic natural history study designed to understand the genetic underpinnings of genetic forms of ALS and the impact on affected families. In addition to overseeing the longitudinal component of the study, she provides predictive genetic counseling services to asymptomatic individuals who are at risk of having inherited an ALS-associated genetic variant. Ms. Harrington is the Pre-Clinical Silence ALS Program genetic counselor and coordinator, a study aimed to discover and develop personalized experimental antisense oligonucleotide (ASO) medicines for ALS patients with rare, disease-causing gene mutations.
Ms. Harrington joined the Department of Neurology faculty in 2019 and is a Lecturer in Genetic Counseling. She is the course director for Biochemical Genetics and Neurogenetics Fieldwork Supervisor for the master’s degree program in Genetic Counseling at the Columbia University Vagelos College of Physicians and Surgeons.
Ms. Harrington directs the ALS Families Project research study, a presymptomatic natural history study designed to understand the genetic underpinnings of genetic forms of ALS and the impact on affected families. In addition to overseeing the longitudinal component of the study, she provides predictive genetic counseling services to asymptomatic individuals who are at risk of having inherited an ALS-associated genetic variant. Ms. Harrington is the Pre-Clinical Silence ALS Program genetic counselor and coordinator, a study aimed to discover and develop personalized experimental antisense oligonucleotide (ASO) medicines for ALS patients with rare, disease-causing gene mutations.
Ms. Harrington joined the Department of Neurology faculty in 2019 and is a Lecturer in Genetic Counseling. She is the course director for Biochemical Genetics and Neurogenetics Fieldwork Supervisor for the master’s degree program in Genetic Counseling at the Columbia University Vagelos College of Physicians and Surgeons.
Ms. Harrington directs the ALS Families Project research study, a presymptomatic natural history study designed to understand the genetic underpinnings of genetic forms of ALS and the impact on affected families. In addition to overseeing the longitudinal component of the study, she provides predictive genetic counseling services to asymptomatic individuals who are at risk of having inherited an ALS-associated genetic variant. Ms. Harrington is the Pre-Clinical Silence ALS Program genetic counselor and coordinator, a study aimed to discover and develop personalized experimental antisense oligonucleotide (ASO) medicines for ALS patients with rare, disease-causing gene mutations.
Ms. Harrington joined the Department of Neurology faculty in 2019 and is a Lecturer in Genetic Counseling. She is the course director for Biochemical Genetics and Neurogenetics Fieldwork Supervisor for the master’s degree program in Genetic Counseling at the Columbia University Vagelos College of Physicians and Surgeons.
Areas of Expertise / Conditions Treated
- Neurogenetics
Academic Appointments
- Lecturer in Genetic Counseling (in Neurology) at the CUMC
Gender
- Female
Schedule an Appointment
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
Insurance Accepted
Aetna
- PPO
Cigna
- EPO
- Great West (National)
- HMO
- Medicare Managed Care
- POS
- PPO
Empire Blue Cross/Blue Shield
- HMO
- Medicare Managed Care
MagnaCare (National)
- MagnaCare
Quality Health Management
- Quality Health Management
UnitedHealthcare
- Compass (Exchange)
- Empire Plan
- HMO
- Oxford Freedom
- Oxford HMO
- Oxford Liberty
- POS
- PPO
World Trade Center Health Plan
- World Trade Center Health Plan
*Please contact the provider’s office directly to verify that your particular insurance is accepted.
Credentials & Experience
Education & Training
- BA, Biology, University of Redlands
- MS, 2017 Human Genetics and Genetic Counseling, Stanford School of Medicine
Honors & Awards
- Heart of Genetic Counseling Award, nominee
- Intramural Research Training Award in the National Human Genome Research Institute
Research
For a complete list of publications, please visit PubMed.gov